000			02231 a2200685 4500
005			20250516051707.0
264		0	_c20111102
008			201111s 0 0 eng d
022			_a1744-8042
024	7		_a10.2217/pgs.11.54 _2doi
040			_aNLM _beng _cNLM
100	1		_avan Schaik, Ron H N
245	0	0	_aThe CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients. _h[electronic resource]
260			_bPharmacogenomics _cAug 2011
300			_a1137-46 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntineoplastic Agents, Hormonal _xtherapeutic use
650	0	4	_aAryl Hydrocarbon Hydroxylases _xgenetics
650	0	4	_aBreast Neoplasms _xdrug therapy
650	0	4	_aCombined Modality Therapy
650	0	4	_aCytochrome P-450 CYP2C19
650	0	4	_aCytochrome P-450 CYP2D6 _xgenetics
650	0	4	_aDNA, Neoplasm _xgenetics
650	0	4	_aData Interpretation, Statistical
650	0	4	_aFemale
650	0	4	_aFollow-Up Studies
650	0	4	_aGenotype
650	0	4	_aHumans
650	0	4	_aLymphatic Metastasis _xpathology
650	0	4	_aMenopause
650	0	4	_aMiddle Aged
650	0	4	_aPharmacogenetics
650	0	4	_aPredictive Value of Tests
650	0	4	_aPrognosis
650	0	4	_aReceptors, Progesterone _xmetabolism
650	0	4	_aRetrospective Studies
650	0	4	_aSurvival Analysis
650	0	4	_aTamoxifen _xtherapeutic use
650	0	4	_aTreatment Outcome
700	1		_aKok, Marleen
700	1		_aSweep, Fred C G J
700	1		_avan Vliet, Martin
700	1		_avan Fessem, Marianne
700	1		_aMeijer-van Gelder, Marion E
700	1		_aSeynaeve, Caroline
700	1		_aLindemans, Jan
700	1		_aWesseling, Jelle
700	1		_aVan 't Veer, Laura J
700	1		_aSpan, Paul N
700	1		_avan Laarhoven, Hanneke
700	1		_aSleijfer, Stefan
700	1		_aFoekens, John A
700	1		_aLinn, Sabine C
700	1		_aBerns, Els M J J
773	0		_tPharmacogenomics _gvol. 12 _gno. 8 _gp. 1137-46
856	4	0	_uhttps://doi.org/10.2217/pgs.11.54 _zAvailable from publisher's website
999			_c21075470 _d21075470